Reference | Author | Year | Metastasis | Regimen of chemotherapy | Patients who underwent gastrectomy | Whole study population (if it included non-surgery cases) | Prognostic factors | ||
---|---|---|---|---|---|---|---|---|---|
Number of patients | MST (months) | Number of patients | MST (months) | ||||||
12 | Nakajima et al. | 1997 | M1 | FLEP (5-Fluorouracil, Leucovorin, Cisplatin, Etoposide) | 19 | NA | 30 | 6.5 | NA |
13 | Yano et al. | 2002 | unresectable (M0 + M1) | FEMTXP (5-Fluorouracil, Epirubicin, Methotrexate, Cisplatin) or THP-FLPM (Pirarubicin,5-Fluorouracil, Leucovorin, Cisplatin, Mitomycin C) | 14 | NA | 33 | NA | salvage surgery |
14 | Satoh et al. | 2006 | M0 + M1 | S-1, Cisplatin | 36 | NA | 45 | 21.8 | NA |
15 | Ishigami et al. | 2008 | M1 | Paclitaxel, S-1 | 18 | 25.7 | – | – | R0 resection |
16 | Okabe et al. | 2009 | M1 (peritoneal metastasis) | S-1, Cisplatin | 32 | NA | 41 | 20.4 | NA |
17 | Suzuki et al. | 2010 | unresectable (M0 + M1) | Docetaxel, S-1 | 20 | 28.5 | – | – | NA |
18 | Kanda et al. | 2012 | M1 | S-1 based chemotherapy | 28 | 29.0 | – | – | histological tumor length (< 5 cm vs. ≥ 5 cm) |
19 | Satoh et al. | 2012 | M1 | S-1, Cisplatin | 44 | NA | 51 | 19.2 | NA |
20 | Han et al. | 2013 | M1 | Various | 34 | 22.9 (R0 resection) and 7.8 (non-R0 resection) | – | – | ypN stage (N0–2 vs. N3) |
21 | Yabusaki et al. | 2013 | M1 | S-1, Cisplatin | 97 | 22.5 | 148 | 16.8 | surgery, R0 resection, D2/D3 lymph node dissection, CR/PR response |
22 | Fukuchi et al. | 2015 | unresectable (M0 + M1) | S-1, Cisplatin or S-1, Paclitaxel | 40 | 53.0 | 151 | 16.0 | one non-curative factor, R0 resection |
23 | Kinoshita et al. | 2015 | M1 | Docetaxel, Cisplatin, S-1 | 34 | 29.9 | 57 | 20.9 | potential resectability |
24 | Ito et al. | 2015 | M1 | Various | 14 | 24.8 | 70 | 14.1 | NA |
Present study | M1 | Various | 101 | 26.0 | – | – | curative resection (complete macroscopic resection), chemotherapy response (CR/PR) of metastatic site, change of CEA level |